ライフサイエンスコーパス: RXR

1 RXR agonists also prevented TNF-alpha-induced VCAM-1 and

2 RXR agonists induced no beneficial effects in the E4FAD-

3 RXR antagonists completely prevented and RXR agonists we

4 RXR deficiency impairs neonatal expansion of the LPM poo

5 RXR remains flexible and adaptive by maintaining loosely

6 RXR signaling is predicted to have a major impact in mac

7 (RXR)4-AcpP increased survival of mice infected with A. l

8 (RXR)4-AcpP reduced viability of A. lwoffii and A. bauman

9 RXR, EcR, and MfR agonists increased storage lipid accum

10 rigenic cells and primary hepatocytes, AEG-1/RXR colocalizes in the nucleus in which AEG-1 interferes

11 Accordingly, RXR-deficient myeloid cells are more efficient in promot

12 ES cells confirmed that bexarotene-activated RXR affected neuronal development at different levels, i

13 olecular mechanisms whereby ligand-activated RXR can affect or restore cognitive functions.

14 We conclude that bexarotene-activated RXRs promote genetic programs involved in the neurogenes

15 eceptor (VDR) and retinoid X receptor-alpha (RXR) has not been investigated.

16 For proliferator-activated receptor alpha/RXR-activated genes, the strongest response was TRG > 4-

17 Our findings are consistent with altered RXR::VDR binding contributing to immunity-related diseas

18 Here, we characterize the compound as an RXR agonist explaining the pleiotropic effects and repor

19 t aortic SMCs were pretreated with either an RXR agonist (bexarotene or 9-cis retinoic acid) or vehic

20 also readily detected by confirmation in an RXR agonist assay.

21 RXR through modeling and then assayed in an RXR-RXR mammalian-2-hybrid (M2H) system and in RXR-respo

22 rodimer and binding of the heterodimer to an RXR-binding site on the Cln2 promoter.

23 Using an RXR-VDR mammalian two-hybrid (M2H) biologic assay system

24 and MerTK and treatment of the cells with an RXR agonist further induced their expression, coincident

25 he full agonist 9a at RXR (pEC50 of 8.2) and RXR-Nurr1.

26 eceptors retinoid X receptor (RXR)-alpha and RXR-beta in mouse epidermal keratinocytes (RXR-alphabeta

27 ear receptors PPARgamma, PPARdelta, LXR, and RXR stimulated microglial phagocytosis in vitro and rapi

28 on of the heterodimer partners PPARgamma and RXR resulted in high dimer activation efficacy.

29 ds as known natural ligands of PPARgamma and RXR, TETRAC differs markedly in its molecular structure

30 RXR antagonists completely prevented and RXR agonists were more effective than RA in inducing neu

31 nal change bringing the N-termini of RAR and RXR closer together.

32 ed through synergistic activation of RAR and RXR nuclear receptors.

33 tissues where it acts by stimulating RAR and RXR receptors, RA signaling during development is absolu

34 Both RAR and RXR signaling events are implicated in hippocampal synap

35 as a novel homeostatic regulator of RXR and RXR/RAR that might contribute to hepatocarcinogenesis.

36 ) are highly enriched in RXR transcripts and RXR-response elements.

37 VDR and RXR expression were assessed by immunohistochemical stai

38 p62 directly interacts with VDR and RXR promoting their heterodimerization, which is critica

39 onstrated interaction between betaCaMKII and RXRs, suggesting that CaMKII pathway regulates the activ

40 r determinants driving activity on PPARs and RXRs.

41 less conserved: Sequences of THRs, RARs and RXRs were >/=90% similar to those of the human, ERs, AR,

42 lysis, we define conserved dual bi-arginine (RXR) motifs that are required for NGF- and phosphoinosit

43 Molecules that function as RXR agonists are of special interest for the prevention

44 reat individuals with metabolic syndrome, as RXR heterodimerizes with multiple nuclear receptors that

45 ional assays, lead to the full agonist 9a at RXR (pEC50 of 8.2) and RXR-Nurr1.

46 SAR of sterically constricted benzofurans at RXR.

47 otein sequence identified an arginine-based (RXR) ER retention sequence located within intracellular

48 y were evaluated for their potential to bind RXR through modeling and then assayed in an RXR-RXR mamm

49 nuclear receptors, can also be activated by RXR agonists known as rexinoids.

50 e nuclear receptor Nurr1 can be activated by RXR via heterodimerization (RXR-Nurr1) and is a promisin

51 ciations were not significantly different by RXR expression.

52 e repression of TR*T3:RXR transactivation by RXR agonists.

53 The approach's validity is underscored by RXR::VDR motif sequence being predictive of binding stre

54 y plastic to a compact form upon binding CAR:RXR.

55 ite on RXR alters the transactivation by CAR:RXR.

56 Functional CAR:RXR heterodimers recruit coactivator proteins, such as t

57 hrough both coactivator binding sites on CAR:RXR, which distinctly bind two SRC1 molecules.

58 VDR-BVs are enriched in consensus RXR::VDR binding motifs, yet most fell outside of these

59 cognizes peptide substrates of the consensus RXR(H/R)X(S/T); it accepts essentially any amino acid at

60 the mollusk Lymnaea stagnalis, two different RXR antagonists (PA452 and HX531) had independent and op

61 uences of C. sapidus and other arthropod EcR/RXR/USP analyzed by in silico indicates a plausible, str

62 between the nuclear receptor heterodimer EcR:RXR and MfR.

63 e requirement of ecdysone binding to the EcR:RXR:MfR complex to regulate lipid storage and that an ex

64 Despite numerous efforts, RXR ligands (rexinoids) have not been approved for clini

65 he recent discoveries of multiple endogenous RXR agonists that mediate physiological tasks such as li

66 nic hepatocytes, overexpressed AEG-1 entraps RXR in cytoplasm, precluding its nuclear translocation.

67 Our results suggest a mechanism to establish RXR therapeutic targets with significance in neurodegene

68 5,11-(6H)dione (AM6-36) (3) is among the few RXR ligands known.

69 acidic moiety that is believed to be key for RXR activation.

70 These data suggest a broader role for RXR within heterodimers, whereas offering multiple strat

71 novel compounds demonstrate selectivity for RXR and minimal crossover onto the retinoic acid recepto

72 e and its distinct substrate specificity for RXR motifs surrounded by basic residues, we performed si

73 Furthermore, RXR agonists increased RXR/PPARgamma interaction, and co

74 reased binding of the nuclear receptors FXR, RXR, HNF4alpha, and LRH-1 to promoter response elements

75 anscriptional activation of lipogenesis, FXR-RXR, PPAR-alpha mediated lipid oxidation and oxidative s

76 uity Pathways Analysis, such as LXR/RXR, FXR/RXR activation (- log[P-value] = 30-31) and atherosclero

77 Signaling via the retinoid X receptor gamma (RXR-gamma) has been shown to be a positive regulator of

78 and retinoic acid receptor-gamma (RAR-gamma)/RXR-beta are bound as repressing complexes to their cogn

79 mer is different from that of the PPAR-gamma-RXR-alpha heterodimer, even when both NR complexes are a

80 be activated by RXR via heterodimerization (RXR-Nurr1) and is a promising target for treating neurod

81 They serve as hallmarks for how RXR changes conformation and dynamics in the presence of

82 ounds based on the interaction with a hybrid RXR and subsequent expression of a reporter luciferase g

83 Here, we identified RXR as an interacting partner of astrocyte-elevated gene

84 Overall, our results identify RXR as a regulator in the myeloid cell-assisted metastat

85 ver, 1 can provoke side effects by impacting RXR-dependent receptor pathways.

86 R-RXR mammalian-2-hybrid (M2H) system and in RXR-responsive element (RXRE)-mediated transcriptional e

87 RXR modulators to overcome key challenges in RXR targeting drug discovery.

88 approach to discover genome-wide changes in RXR cistrome (ChIP-Seq) and gene expression profile (RNA

89 us-cavity TRMs (LPMs) are highly enriched in RXR transcripts and RXR-response elements.

90 nify an isoform-specific role for Akt/PKB in RXR-selective signaling to promote and to retain myoblas

91 es, thereby affecting signal transmission in RXR heterodimers.

92 Furthermore, RXR agonists increased RXR/PPARgamma interaction, and combinations of suboptima

93 We found bexarotene increased RXR binding to promoter regions in cortex of APOE3 mice.

94 Many individual RXR heterodimers have beneficial effects in vascular smo

95 Upon interaction, AEG-1 profoundly inhibited RXR/retinoic acid receptor (RAR)-mediated transcriptiona

96 e astrocyte elevated gene-1 (AEG-1) inhibits RXR-dependent transcription and activates NF-kappaB.

97 with retinoid X receptor (RXR) and inhibits RXR function.

98 ds, it establishes a new class of innovative RXR modulators to overcome key challenges in RXR targeti

99 wo ligand-dependent signalling pathways into RXR heterodimer-specific responses.

100 d RXR-beta in mouse epidermal keratinocytes (RXR-alphabeta(ep-/-)) or a topical application of active

101 Using these features, 387 liganded RXR-bound enhancers were linked to 226 genes, which pred

102 h datasets revealed that bexarotene-liganded RXR affected signaling pathways associated with neurogen

103 iogenic genes, including Vegfa, has liganded RXR-controlled enhancers and provides the macrophage wit

104 ide studies were carried out to map liganded RXR-mediated transcriptional changes, active binding sit

105 ched in both datasets revealed that liganded RXR affected signaling pathways associated with neurogen

106 LXR/RXR activation and complement activation pathways were e

107 In the absence of MafB, activated LXR/RXR fails to induce the expression of AIM, a protein tha

108 MafB mediates the oxidized LDL-activated LXR/RXR-induced expression of apoptosis inhibitor of macroph

109 by Ingenuity Pathways Analysis, such as LXR/RXR, FXR/RXR activation (- log[P-value] = 30-31) and ath

110 ogically distinct macrophages identified LXR/RXR as the most enriched pathway in large macrophages, w

111 Biological pathway analyses implicate LXR/RXR activation, neuroinflammation, atherosclerosis signa

112 ment." The top enriched pathways include LXR/RXR Activation and Atherosclerosis Signaling, etc.

113 icrobiota play a role in arsenic-induced LXR/RXR signaling inhibition and the subsequent lipid and ch

114 itical factor regulating arsenic-induced LXR/RXR signaling perturbation, suggesting that modulation o

115 ed liver X receptor/retinoid X receptor (LXR/RXR) signaling inhibition is a potential mechanism under

116 pression levels of genes associated with LXR/RXR signaling were quantified by quantitative real-time

117 in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces so

118 Agonists of nuclear receptors LXR:RXR and PPAR:RXR act to ameliorate AD-related cognitive

119 The macrophage RXR cistrome has 5200 genomic binding sites, which are n

120 use rexinoids can potently activate multiple RXR pathways, we hypothesized that treating SMCs with re

121 ility that constitutive activity of neuronal RXR and/or RAR alters calcium influx via the VGCCs.

122 dic and nonacidic indenoisoquinolines as new RXR ligands.

123 Thus, our studies have uncovered a novel RXR-dependent innate immune regulatory pathway, suggesti

124 However, although the mechanism of action of RXR agonists remains unclear, a major concern for their

125 tiation and fusion through the activation of RXR and the regulation of Akt/PKB isoform-specific expre

126 ese functional studies, ligand activation of RXR inhibits the expression of antiviral genes including

127 r results indicate that ligand activation of RXR suppresses the nuclear translocation of beta-catenin

128 sion, low SREBP induction, and activation of RXR, MSU-42011 was selected as our lead compound.

129 -1KO mice, we observed increased activity of RXR heterodimer partners, liver X receptor and peroxisom

130 ults suggest that the repressive activity of RXR on prometastatic genes is mediated primarily through

131 this study, we demonstrate that deletion of RXR in myeloid cells enhances lung metastasis formation

132 thway, suggesting that the downregulation of RXR expression or RXR antagonist treatment benefits host

133 in animals exposed to different effectors of RXR, EcR, and MfR signaling pathways, either individuall

134 ake them an attractive and unusual family of RXR agonists.

135 last differentiation due to the formation of RXR/liver X receptor (LXR) heterodimers, which induced e

136 he RXR agonist increased homodimerization of RXR suggesting that RXR may act as an autonomous transcr

137 R represses MMP7 expression independently of RXR.

138 6 signaling, LPS/IL-1-mediated inhibition of RXR Function, PI3K in B lymphocytes, iCOS-iCOSL in T hel

139 additional activation of IL-1/inhibition of RXR, granulocyte diapedesis/adhesion, Fc macrophage acti

140 With its lack of RXR/liver X receptor-mediated side effects and superior

141 Loss of RXR function in hematopoietic cells resulted in formatio

142 results suggest that optimized modulation of RXR may be a promising strategy to treat metabolic disor

143 the nuclear receptor (NR) binding partner of RXR-gamma has not been established.

144 mally addresses the ligand binding pocket of RXR.

145 n a potentially limiting/sequestered pool of RXR and simultaneous expression of several RXR partners,

146 es AEG-1 as a novel homeostatic regulator of RXR and RXR/RAR that might contribute to hepatocarcinoge

147 The significance of RXR for these functions was validated in mouse embryonic

148 To further validate the significance of RXR for these functions, we used mouse embryonic stem (E

149 Pharmacological activation of RXRs inhibited osteoclast differentiation due to the for

150 t CaMKII pathway regulates the activities of RXRs.

151 Mice treated with >/=0.25 mg/kg of (RXR)4-AcpP survived longer and had less inflammation and

152 re we examine if the effect of bexarotene on RXR cistrome and transcriptomes depend on APOE isoform a

153 how that disrupting the SRC1 binding site on RXR alters the transactivation by CAR:RXR.

154 rug comprising selective and dual agonism on RXRs and PPARs that may serve as superior pharmacologica

155 that the downregulation of RXR expression or RXR antagonist treatment benefits host antiviral respons

156 ers communicate with promoters via stable or RXR-induced loops and that some of the enhancers interac

157 can elicit side-effects by disrupting other RXR-heterodimer receptor pathways.

158 analogues also reducing inhibition of other RXR-dependent pathways (e.g., VDR-RXR).

159 europrotective role and indicated that other RXR ligands could have therapeutic potential in Parkinso

160 the VDR along with its heterodimeric partner RXR to the negative vitamin D response element on the pr

161 ion, ERK, activated by AEG-1, phosphorylates RXR that leads to its functional inactivation and attenu

162 A systematically optimized high potency RXR agonist revealed activity in vivo and active concent

163 l-UAB30, an analogue of 9cUAB30, is a potent RXR agonist but caused increased lipid biosynthesis unli

164 results suggest that modifications of potent RXR agonists such as NEt-TMN can lead to improved biolog

165 ctivators of the omega-3 LCPUFA sensing PPAR-RXR axis may influence retinal angiogenesis in NV AMD vi

166 onists of nuclear receptors LXR:RXR and PPAR:RXR act to ameliorate AD-related cognitive impairment an

167 , likely as the result of enhanced PPARalpha/RXR activity and improved mitochondrial function.

168 ced PPARalpha/retinoid X receptor (PPARalpha/RXR) activity and downstream signaling pathways in glome

169 e demonstrate that TETRAC promotes PPARgamma/RXR signaling in cell-free, cellular, and in vivo settin

170 and in the C-terminus, organized as putative RXR motifs.

171 r "xenobiotic metabolism signaling" and "PXR/RXR activation" pathways.

172 viously demonstrated that retinoic acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers rec

173 Our data imply that RAR agonist enhances RAR-RXR heterodimerization, and chromatin binding/dimerizati

174 The differential ability of RAR-RXR bound to DR0 compared to DR2, DR5, and DR8 to mediat

175 Recombinant RAR-RXR binds these non-canonical spacings in vitro with com

176 and topology of binding elements for the RAR-RXR heterodimer.

177 dermal fibroblasts and is regulated via RAR/RXR-mediated pathways.

178 tivation by recruiting co-regulators and RAR:RXR or beta-catenin, suggesting an unexpected collaborat

179 he use of an agonist to the nuclear receptor RXR, bexarotene, as monotherapy against AD, presents pot

180 ers such as TR:9-cis retinoic acid receptor (RXR).

181 assessed for selective retinoid X receptor (RXR) agonism.

182 that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta

183 Examination of three retinoid X receptor (RXR) agonists [Targretin (TRG), UAB30, and 4-methyl-UAB3

184 activate or antagonize retinoid X receptor (RXR) alpha.

185 liver X receptor (LXR)/retinoid X receptor (RXR) and farnesoid X receptor/RXR nuclear receptor signa

186 AEG-1 interacts with retinoid X receptor (RXR) and inhibits RXR function.

187 ch heterodimerizes with retinoid X receptor (RXR) and regulates transcription of target genes, such a

188 se of the activation of retinoid X receptor (RXR) at very low environmental concentrations.

189 ificantly decreased FXR/retinoid X receptor (RXR) binding affinity but enhanced the interaction of FX

190 r gamma (PPARgamma) and retinoid X receptor (RXR) by classical and nonclassical THs as another molecu

191 itamin D receptor (VDR)-retinoid X receptor (RXR) complex and drove reporter gene transcription in re

192 Targeting retinoid X receptor (RXR) has been proposed as one of the therapeutic strateg

193 eptor-alpha (PPARalpha)/retinoid X receptor (RXR) heterodimer promotes transcription of genes involve

194 nal target for the NR4A-retinoid X receptor (RXR) heterodimer.

195 acid receptor (RAR) and retinoid X receptor (RXR) is revealed, and an extension of the molecular swit

196 acid receptor (RAR) and retinoid X receptor (RXR) mediate the cellular effects of retinoids (derivati

197 The retinoid X receptor (RXR) partners with numerous nuclear receptors, such as t

198 Retinoid X receptor (RXR) plays a pivotal role as a transcriptional regulator

199 , in particular, of the retinoid X receptor (RXR) positioned nuclear receptors at the epicenter of th

200 Retinoid X receptor (RXR) regulates key cellular responses such as cell growt

201 Retinoid X receptor (RXR) regulates several key functions in myeloid cells, i

202 R) FokI AA genotype and retinoid X receptor (RXR) rs7861779 TT genotype were associated with increase

203 and evaluated for their retinoid X receptor (RXR) selective agonism.

204 iption factors with the retinoid X receptor (RXR) to regulate diverse biological processes in respons

205 he LCPUFA-sensing PPARG-retinoid X receptor (RXR) transcription complex, may influence neovasculariza

206 igate heterodimers with retinoid X receptor (RXR), allowing integration of ligand-dependent signals a

207 receptors, such as the retinoid X receptor (RXR), are proteins that regulate a myriad of cellular pr

208 rodimerization with the retinoid X receptor (RXR), indicating that FXR represses MMP7 expression inde

209 ated with regulation by retinoid X receptor (RXR), jun proto-oncogene (JUN), sine oculis homeobox fac

210 ligate heterodimer with retinoid X receptor (RXR), PPARgamma binds directly repeated nuclear receptor

211 Activation of the retinoid X receptor (RXR), which is involved in cell proliferation, different

212 f the nuclear receptors retinoid X receptor (RXR)-alpha and RXR-beta in mouse epidermal keratinocytes

213 ranscription regulation retinoid X receptor (RXR)-liver X receptor (LXR) system.

214 gical processes through retinoid X receptor (RXR)-mediated gene expression, molecular pathways underl

215 erodimerization partner retinoid X receptor (RXR).

216 and Ultraspiracle (USP)/Retinoid-X Receptor (RXR).

217 rough activation of the retinoid X receptor (RXR).

218 a heterodimer with the Retinoid X receptor (RXR).

219 Because the effect of retinoid X receptor (RXR)alpha on arterial mononuclear leukocyte recruitment

220 ivated or antagonized retinoid "X" receptor (RXR) or PPARgamma in transient transfection assays.

221 eterodimer partner, the retinoid-X-receptor (RXR), was also readily detected by confirmation in an RX

222 in (agonist of the retinoid X acid receptor, RXR).

223 id X receptor (RXR) and farnesoid X receptor/RXR nuclear receptor signaling among pleiotropic genes a

224 Many liver X receptor/RXR-related genes (e.g., Scd-1 and Srebf1, which are ass

225 e androstane (CAR) and retinoid X receptors (RXR) are ligand-mediated transcription factors of the nu

226 selective agonist for Retinoid X receptors (RXR) improves cognitive deficits and amyloid-beta (Abeta

227 a, -beta, -gamma), and retinoid X receptors (RXR-alpha, -beta, -gamma) was performed on tissue sample

228 eceptor (RAR-beta) and retinoid X receptors (RXR-beta, -gamma) was significantly upregulated in sebac

229 target retinoid and retinoic acid receptors (RXRs and RARs), leading to physiological and pharmacolog

230 Bexarotene-activated retinoid X receptors (RXRs) ameliorate memory deficits in Alzheimer's disease

231 s) heterodimerize with retinoid X receptors (RXRs) and bind to RA response elements (RAREs) in the re

232 lear receptor families retinoid X receptors (RXRs) and peroxisome proliferator-activated receptors (P

233 e, we demonstrate that retinoid X receptors (RXRs) are key elements of the transcriptional program of

234 Retinoid X receptors (RXRs) are obligate partners for several other nuclear re

235 genesis, we found that retinoid X receptors (RXRs) control neuritogenesis.

236 ners of PPARgamma, the retinoid X receptors (RXRs), showed additive enhancement of the Abeta uptake t

237 ) signaling, including retinoid X receptors (RXRs).

238 In this regard resonant x-ray reflectivity (RXR) provides a unique experimental tool to achieve exac

239 arginine residues separated by one residue (RXR motif).

240 eral compounds also displayed more selective RXR activation with minimal cross-signaling of the retin

241 ervention through activation using selective RXR agonists (rexinoids).

242 f RXR and simultaneous expression of several RXR partners, we hypothesized that NRs compete for bindi

243 led novel compounds, all analogues stimulate RXR-regulated transcription in mammalian 2 hybrid and RX

244 ctural mechanism for the repression of TR*T3:RXR transactivation by RXR agonists.

245 gment show lower affinities (K(a)) for TR*T3:RXR*9c than TR*T3:RXR.

246 ffinities (K(a)) for TR*T3:RXR*9c than TR*T3:RXR.

247 scattering (SAXS) we show that the CAR(tcp):RXR(9c).SRC1 complex can encompass two SRC1 molecules co

248 wo SRC1 molecules compared with the CAR(tcp):RXR.SRC1, which binds only a single SRC1.

249 In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) i

250 Ms infiltrate early ovarian tumours and that RXR deletion diminishes LPM accumulation in tumours and

251 titative co-localization with chromatin that RXR immobilization and co-localization with chromatin ar

252 These data demonstrate that RXR is a potent modulator of angiotensin II-mediated res

253 -delta (YBCO) thin film, we demonstrate that RXR is further capable to deliver site selectivity.

254 This puts forward the possibility that RXR activation and increased levels of ABCA1 and ABCG1 c

255 Therefore, these results reveal that RXR agonists can inhibit the initial inflammatory respon

256 of osteoclast progenitor cells revealed that RXR homodimers directly target and bind to the Mafb prom

257 Our study reveals that RXR signaling mediates bone homeostasis and suggests tha

258 Our study reveals that RXR signalling controls the maintenance of the serous ma

259 We show that RXR deficiency leads to transcriptomic changes in the lu

260 In this study we show that RXR-gamma binds to several NRs in OPCs and OLGs, one of

261 ogical and knockdown approaches we show that RXR-VDR signaling induces OPC differentiation and that V

262 The results showed that RXR ligands could increase neurotrophic signaling, but p

263 ased homodimerization of RXR suggesting that RXR may act as an autonomous transcription factor.

264 Here, we show that RXRs control mouse serous-macrophage identity by regulat

265 mediates bone homeostasis and suggests that RXRs have potential as targets for the treatment of bone

266 The RXR agonist increased homodimerization of RXR suggesting

267 that, in vivo within their heterodimers, the RXR and RAR isotypes are not functionally redundant, and

268 ial for multicellular life, highlighting the RXR heterodimer and its associated ligands and transcrip

269 nt study, we investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apo

270 are conserved in all x-ray structures of the RXR ligand-binding domain in the presence of agonist and

271 iciency was due to lack of expression of the RXR-dependent transcription factor v-maf musculoaponeuro

272 ganotin compounds and natural ligands of the RXR.

273 We reported previously that the RXR-type dibasic motif in the distal C-terminal tail of

274 ) that were also time-dependent; whereas the RXR pan-antagonist PA452 enhanced I (Ca), HX531 reduced

275 s show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognit

276 lates critical steps of adipogenesis through RXR/PPARgamma and that prenatal TBT exposure predisposes

277 Thus, RXR activation stimulates physiological Abeta clearance

278 Thus, RXR agonists address the loss-of-function associated wit

279 Thus, RXR agonists may constitute a new therapeutic tool in th

280 Thus, RXRs are in the final common path and may be therapeutic

281 hypothesized that NRs compete for binding to RXR and that this competition is directed by specific ag

282 Agonist binding to RXR initiates a large conformational change in the recep

283 cruitment of transcriptional coactivators to RXR, preventing transcription of target genes.

284 Inhibition of co-activator recruitment to RXR and activation of NF-kappaB were identified to play

285 By applying a new analysis scheme to RXR, which takes the atomic structure of the material in

286 ve cooperativity in ligand binding within TR:RXR heterodimers.

287 ded heterodimers of vitamin D receptor (VDR)/RXR-alpha and retinoic acid receptor-gamma (RAR-gamma)/R

288 at -28 kb that 1,25D-dependently docked VDR, RXR, C/EBPbeta, and RUNX2.

289 n of other RXR-dependent pathways (e.g., VDR-RXR).

290 acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers recruit only one coactivator molecule

291 eterodimerization, which is critical for VDR:RXR target gene recruitment.

292 The most effective PPMO tested was (RXR)4-AcpP, which is targeted to acpP.

293 nt benefits host antiviral response, whereas RXR agonist treatment may increase the risk of viral inf

294 Further studies are vital to address whether RXR agonists are an APOE4-specific AD therapeutic and th

295 understood, this study investigated whether RXR agonists can affect this response and the underlying

296 e show an allosteric mechanism through which RXR co-operates with a permissive dimer partner, peroxis

297 The increase in bone mass associated with RXR deficiency was due to lack of expression of the RXR-

298 and/or liver X receptor in conjunction with RXR.

299 d no significant effects on interaction with RXR.

300 LXRs interact/cooperate with RXRs and result in the activation of StAR gene transcrip